These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28111042)

  • 101. The emerging world of breast cancer immunotherapy.
    Nathan MR; Schmid P
    Breast; 2018 Feb; 37():200-206. PubMed ID: 28583398
    [TBL] [Abstract][Full Text] [Related]  

  • 102. [Pathological advances in renal, prostatic, bladder and testis neoplasia].
    Rioux-Leclercq N; Comperat E; Kammerer-Jacquet SF; Camparo P; Fromont G;
    Prog Urol; 2016 Jun; 26(8):477-83. PubMed ID: 27473787
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma.
    Lattanzi M; Balar AV
    Curr Oncol Rep; 2019 Feb; 21(3):24. PubMed ID: 30806823
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Emerging Immunotargets in Metastatic Renal Cell Carcinoma.
    Kucharczyk J; Matrana MR; Santoni M; Massari F; Scarpelli M; Cheng L; Lopez-Beltran A; Cascinu S; Montironi R; Holger M
    Curr Drug Targets; 2016; 17(7):771-6. PubMed ID: 26648075
    [TBL] [Abstract][Full Text] [Related]  

  • 105. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Immunological evaluation in patients with urological cancers.
    Martinez-Piñeiro JA; Muntanola P; Hidalgo L
    Eur Urol; 1977; 3(3):159-62. PubMed ID: 560302
    [TBL] [Abstract][Full Text] [Related]  

  • 108. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Immunotherapy advances in uro-genital malignancies.
    Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
    Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Revisiting Immunotherapy: A Focus on Prostate Cancer.
    Cha HR; Lee JH; Ponnazhagan S
    Cancer Res; 2020 Apr; 80(8):1615-1623. PubMed ID: 32066566
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Necchi A; Giardiello D; Mariani L
    Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
    [No Abstract]   [Full Text] [Related]  

  • 112. Novel biomarkers in bladder cancer.
    Cheng ML; Iyer G
    Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Immunotherapy in genitourinary neoplasia.
    Droller MJ
    J Urol; 1985 Jan; 133(1):1-5. PubMed ID: 2578065
    [No Abstract]   [Full Text] [Related]  

  • 114. The cancer associated antigen test as an index to failure of complete removal of urological cancers.
    Wechsler M; Lo Gerfo P; Feminella J; Lattimer JK
    Trans Am Assoc Genitourin Surg; 1972; 64():85-7. PubMed ID: 4347503
    [No Abstract]   [Full Text] [Related]  

  • 115. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.
    Bracarda S; Altavilla A; Hamzaj A; Sisani M; Marrocolo F; Del Buono S; Danielli R
    Semin Oncol; 2015 Jun; 42(3):495-505. PubMed ID: 25965369
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
    Sun R; Champiat S; Dercle L; Aspeslagh S; Castanon E; Limkin EJ; Baldini C; Postel-Vinay S; Hollebecque A; Massard C; Ammari S; Deutsch E; Soria JC; Marabelle A; Ferté C
    Eur J Cancer; 2017 Oct; 84():202-211. PubMed ID: 28826073
    [TBL] [Abstract][Full Text] [Related]  

  • 118. [Urogenital cancer].
    Koiso K; Rinsho K; Nemoto R; Ishikawa H; Ohtani M; Uchida K; Noguchi R
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):971-7. PubMed ID: 2658819
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

  • 120. [Immunotherapy in the treatment of genitourinary cancers].
    Géczi L; Ladányi A; Vajdics T; Küronya Z; Bíró K; Gyergyay F; Martin T; Nagyiványi K
    Magy Onkol; 2016 Mar; 60(1):41-5. PubMed ID: 26934350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.